Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.

Hammond SM, Abendroth F, Gait MJ, Wood MJA.

Methods Mol Biol. 2019;2036:221-236. doi: 10.1007/978-1-4939-9670-4_13.

PMID:
31410800
2.

Family violence in Victoria, Australia: a retrospective case-control study of forensic medical casework.

Zark L, Hammond SM, Williams A, Pilgrim JL.

Int J Legal Med. 2019 Sep;133(5):1537-1547. doi: 10.1007/s00414-019-02000-9. Epub 2019 Jan 25.

PMID:
30684004
3.

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.

Betts CA, McClorey G, Healicon R, Hammond SM, Manzano R, Muses S, Ball V, Godfrey C, Merritt TM, van Westering T, O'Donovan L, Wells KE, Gait MJ, Wells DJ, Tyler D, Wood MJ.

Hum Mol Genet. 2019 Feb 1;28(3):396-406. doi: 10.1093/hmg/ddy346.

4.

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice.

Walter LM, Deguise MO, Meijboom KE, Betts CA, Ahlskog N, van Westering TLE, Hazell G, McFall E, Kordala A, Hammond SM, Abendroth F, Murray LM, Shorrock HK, Prosdocimo DA, Haldar SM, Jain MK, Gillingwater TH, Claus P, Kothary R, Wood MJA, Bowerman M.

EBioMedicine. 2018 May;31:226-242. doi: 10.1016/j.ebiom.2018.04.024. Epub 2018 May 4.

5.

Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy.

Shabanpoor F, Hammond SM, Abendroth F, Hazell G, Wood MJA, Gait MJ.

Nucleic Acid Ther. 2017 Jun;27(3):130-143. doi: 10.1089/nat.2016.0652. Epub 2017 Jan 24.

6.

Mature neurons dynamically restrict apoptosis via redundant premitochondrial brakes.

Annis RP, Swahari V, Nakamura A, Xie AX, Hammond SM, Deshmukh M.

FEBS J. 2016 Dec;283(24):4569-4582. doi: 10.1111/febs.13944. Epub 2016 Nov 18.

7.

Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.

Hammond SM, Hazell G, Shabanpoor F, Saleh AF, Bowerman M, Sleigh JN, Meijboom KE, Zhou H, Muntoni F, Talbot K, Gait MJ, Wood MJ.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10962-7. doi: 10.1073/pnas.1605731113. Epub 2016 Sep 12.

8.

Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS.

Emde A, Eitan C, Liou LL, Libby RT, Rivkin N, Magen I, Reichenstein I, Oppenheim H, Eilam R, Silvestroni A, Alajajian B, Ben-Dov IZ, Aebischer J, Savidor A, Levin Y, Sons R, Hammond SM, Ravits JM, Möller T, Hornstein E.

EMBO J. 2015 Nov 3;34(21):2633-51. doi: 10.15252/embj.201490493. Epub 2015 Sep 1.

9.

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.

Betts CA, Saleh AF, Carr CA, Muses S, Wells KE, Hammond SM, Godfrey C, McClorey G, Woffindale C, Clarke K, Wells DJ, Gait MJ, Wood MJ.

Sci Rep. 2015 Jun 26;5:11632. doi: 10.1038/srep11632.

10.

Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases.

Varela MA, Curtis HJ, Douglas AG, Hammond SM, O'Loughlin AJ, Sobrido MJ, Scholefield J, Wood MJ.

Eur J Hum Genet. 2016 Feb;24(2):271-6. doi: 10.1038/ejhg.2015.94. Epub 2015 May 20.

11.

An overview of microRNAs.

Hammond SM.

Adv Drug Deliv Rev. 2015 Jun 29;87:3-14. doi: 10.1016/j.addr.2015.05.001. Epub 2015 May 12. Review.

12.

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.

Betts CA, Saleh AF, Carr CA, Hammond SM, Coenen-Stass AM, Godfrey C, McClorey G, Varela MA, Roberts TC, Clarke K, Gait MJ, Wood MJ.

Sci Rep. 2015 Mar 11;5:8986. doi: 10.1038/srep08986.

13.

Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides.

Järver P, Zaghloul EM, Arzumanov AA, Saleh AF, McClorey G, Hammond SM, Hällbrink M, Langel Ü, Smith CI, Wood MJ, Gait MJ, El Andaloussi S.

Nucleic Acid Ther. 2015 Apr;25(2):65-77. doi: 10.1089/nat.2014.0511. Epub 2015 Jan 16.

14.

Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides.

Hammond SM, McClorey G, Nordin JZ, Godfrey C, Stenler S, Lennox KA, Smith CI, Jacobi AM, Varela MA, Lee Y, Behlke MA, Wood MJ, Andaloussi SE.

Mol Ther Nucleic Acids. 2014 Nov 25;3:e212. doi: 10.1038/mtna.2014.63.

15.

Design and application of bispecific splice-switching oligonucleotides.

Bestas B, McClorey G, Tedebark U, Moreno PM, Roberts TC, Hammond SM, Smith CI, Wood MJ, Andaloussi SE.

Nucleic Acid Ther. 2014 Feb;24(1):13-24. doi: 10.1089/nat.2013.0462.

PMID:
24506779
16.

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.

Betts C, Saleh AF, Arzumanov AA, Hammond SM, Godfrey C, Coursindel T, Gait MJ, Wood MJ.

Mol Ther Nucleic Acids. 2012 Aug 14;1:e38. doi: 10.1038/mtna.2012.30.

17.

DiffSplice: the genome-wide detection of differential splicing events with RNA-seq.

Hu Y, Huang Y, Du Y, Orellana CF, Singh D, Johnson AR, Monroy A, Kuan PF, Hammond SM, Makowski L, Randell SH, Chiang DY, Hayes DN, Jones C, Liu Y, Prins JF, Liu J.

Nucleic Acids Res. 2013 Jan;41(2):e39. doi: 10.1093/nar/gks1026. Epub 2012 Nov 15.

18.

Primitive erythropoiesis is regulated by miR-126 via nonhematopoietic Vcam-1+ cells.

Sturgeon CM, Chicha L, Ditadi A, Zhou Q, McGrath KE, Palis J, Hammond SM, Wang S, Olson EN, Keller G.

Dev Cell. 2012 Jul 17;23(1):45-57. doi: 10.1016/j.devcel.2012.05.021. Epub 2012 Jun 28.

19.

Use of cell-penetrating-peptides in oligonucleotide splice switching therapy.

El Andaloussi SA, Hammond SM, Mäger I, Wood MJ.

Curr Gene Ther. 2012 Jun;12(3):161-78. Review.

PMID:
22533378
20.

Optimizing tissue-specific antisense oligonucleotide-peptide conjugates.

Betts CA, Hammond SM, Yin HF, Wood MJ.

Methods Mol Biol. 2012;867:415-35. doi: 10.1007/978-1-61779-767-5_27.

PMID:
22454077
21.

A psychometric appraisal of the DREEM.

Hammond SM, O'Rourke M, Kelly M, Bennett D, O'Flynn S.

BMC Med Educ. 2012 Jan 12;12:2. doi: 10.1186/1472-6920-12-2.

22.

Determinants of mRNA recognition and translation regulation by Lin28.

Lei XX, Xu J, Ma W, Qiao C, Newman MA, Hammond SM, Huang Y.

Nucleic Acids Res. 2012 Apr;40(8):3574-84. doi: 10.1093/nar/gkr1279. Epub 2011 Dec 30.

23.

Deep sequencing of microRNA precursors reveals extensive 3' end modification.

Newman MA, Mani V, Hammond SM.

RNA. 2011 Oct;17(10):1795-803. doi: 10.1261/rna.2713611. Epub 2011 Aug 17.

24.

miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.

Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM, MacPherson D.

Genes Dev. 2011 Aug 15;25(16):1734-45. doi: 10.1101/gad.17027411. Epub 2011 Aug 4.

25.

Genetic therapies for RNA mis-splicing diseases.

Hammond SM, Wood MJ.

Trends Genet. 2011 May;27(5):196-205. doi: 10.1016/j.tig.2011.02.004. Epub 2011 Apr 15. Review.

PMID:
21497936
26.

PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation.

Ezzat K, Andaloussi SE, Zaghloul EM, Lehto T, Lindberg S, Moreno PM, Viola JR, Magdy T, Abdo R, Guterstam P, Sillard R, Hammond SM, Wood MJ, Arzumanov AA, Gait MJ, Smith CI, Hällbrink M, Langel Ü.

Nucleic Acids Res. 2011 Jul;39(12):5284-98. doi: 10.1093/nar/gkr072. Epub 2011 Feb 23.

27.

Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late.

Hammond SM, Gogliotti RG, Rao V, Beauvais A, Kothary R, DiDonato CJ.

PLoS One. 2010 Dec 29;5(12):e15887. doi: 10.1371/journal.pone.0015887.

28.

miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis.

Kole AJ, Swahari V, Hammond SM, Deshmukh M.

Genes Dev. 2011 Jan 15;25(2):125-30. doi: 10.1101/gad.1975411.

29.

Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.

Zimmerman EI, Dollins CM, Crawford M, Grant S, Nana-Sinkam SP, Richards KL, Hammond SM, Graves LM.

Mol Pharmacol. 2010 Nov;78(5):811-7. doi: 10.1124/mol.110.066258. Epub 2010 Aug 6.

30.

PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.

Hammond SM, Wood MJ.

Curr Opin Mol Ther. 2010 Aug;12(4):478-86.

PMID:
20677099
31.

MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.

Du L, Schageman JJ, Irnov, Girard L, Hammond SM, Minna JD, Gazdar AF, Pertsemlidis A.

J Exp Clin Cancer Res. 2010 Jun 17;29:75. doi: 10.1186/1756-9966-29-75.

32.

Lin-28: an early embryonic sentinel that blocks Let-7 biogenesis.

Newman MA, Hammond SM.

Int J Biochem Cell Biol. 2010 Aug;42(8):1330-3. doi: 10.1016/j.biocel.2009.02.023. Epub 2009 Mar 9.

PMID:
20619222
33.

Emerging paradigms of regulated microRNA processing.

Newman MA, Hammond SM.

Genes Dev. 2010 Jun 1;24(11):1086-92. doi: 10.1101/gad.1919710. Review.

34.

A putative role for microRNA-205 in mammary epithelial cell progenitors.

Greene SB, Gunaratne PH, Hammond SM, Rosen JM.

J Cell Sci. 2010 Feb 15;123(Pt 4):606-18. doi: 10.1242/jcs.056812. Epub 2010 Jan 26.

35.

Toxoplasma gondii infection specifically increases the levels of key host microRNAs.

Zeiner GM, Norman KL, Thomson JM, Hammond SM, Boothroyd JC.

PLoS One. 2010 Jan 15;5(1):e8742. doi: 10.1371/journal.pone.0008742.

36.

Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy.

Gogliotti RG, Hammond SM, Lutz C, Didonato CJ.

Biochem Biophys Res Commun. 2010 Jan 1;391(1):517-22. doi: 10.1016/j.bbrc.2009.11.090. Epub 2009 Dec 4.

37.

Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells.

Banerjee A, Schambach F, DeJong CS, Hammond SM, Reiner SL.

Eur J Immunol. 2010 Jan;40(1):225-31. doi: 10.1002/eji.200939381.

38.

miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1.

Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD, Pertsemlidis A.

Mol Cancer Res. 2009 Aug;7(8):1234-43. doi: 10.1158/1541-7786.MCR-08-0507. Epub 2009 Aug 11.

39.

Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7.

Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR.

EMBO J. 2009 Feb 18;28(4):347-58. doi: 10.1038/emboj.2008.294. Epub 2009 Jan 15.

40.

Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance.

Xin F, Li M, Balch C, Thomson M, Fan M, Liu Y, Hammond SM, Kim S, Nephew KP.

Bioinformatics. 2009 Feb 15;25(4):430-4. doi: 10.1093/bioinformatics/btn646. Epub 2008 Dec 17.

41.

HMGA2, microRNAs, and stem cell aging.

Hammond SM, Sharpless NE.

Cell. 2008 Dec 12;135(6):1013-6. doi: 10.1016/j.cell.2008.11.026. Review.

42.

Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing.

Newman MA, Thomson JM, Hammond SM.

RNA. 2008 Aug;14(8):1539-49. doi: 10.1261/rna.1155108. Epub 2008 Jun 19.

43.

Fgf-dependent depletion of microRNA-133 promotes appendage regeneration in zebrafish.

Yin VP, Thomson JM, Thummel R, Hyde DR, Hammond SM, Poss KD.

Genes Dev. 2008 Mar 15;22(6):728-33. doi: 10.1101/gad.1641808.

44.

Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure.

Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, Meissner G, Patterson C, Hannon GJ, Wang DZ.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2111-6. doi: 10.1073/pnas.0710228105. Epub 2008 Feb 6.

45.
46.

Soaking up small RNAs.

Hammond SM.

Nat Methods. 2007 Sep;4(9):694-5. No abstract available.

PMID:
17762876
47.

Microarray analysis of miRNA gene expression.

Thomson JM, Parker JS, Hammond SM.

Methods Enzymol. 2007;427:107-22.

PMID:
17720481
48.

Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy.

Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ.

J Mol Cell Cardiol. 2007 Jun;42(6):1137-41. Epub 2007 Apr 14.

49.

MicroRNAs as tumor suppressors.

Hammond SM.

Nat Genet. 2007 May;39(5):582-3. No abstract available.

PMID:
17460676
50.

microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder.

Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, Parker JS, Jin J, Hammond SM.

Genome Biol. 2007;8(2):R27.

Supplemental Content

Loading ...
Support Center